Jazz Pharmaceuticals plc
) recently discussed its product portfolio and pipeline. Key
products in the company's portfolio include Xyrem, Erwinaze and
Xyrem (sodium oxybate) is available in the US market since 2002
for cataplexy and excessive daytime sleepiness in narcolepsy. The
specialty biopharmaceutical company stated that it expects to
meet the guidance of Xyrem 2012 sales ranging $375-$380 million,
announced in Nov 2012. The company is currently facing patent
challenges for Xyrem. Two abbreviated new drug applications
(ANDA) have been filed out of which litigation going on with one.
Jazz Pharma added Erwinaze (asparaginase Erwinia chrysanthemi) to
its product portfolio following its EUSA Pharma acquisition in
Jun 2012. Erwinaze is used for the treatment of patients
suffering from acute lymphoblastic leukemia (ALL) with
hypersensitivity to E. coli-derived asparaginase therapy. The
company expects to exceed the guidance of $125-$129 million in
2012. The product enjoys orphan drug exclusivity in the US till
The company has initiated a study evaluating intravenous
formulation Erwinaze. Jazz Pharma expects preliminary
pharmacokinetic data from the study in the second half of 2013.
Jazz Pharma added chronic pain treatment Prialt to its product
portfolio through its acquisition of Azur Pharma in Jan 2012. In
the first half of 2013, the company intends to initiate a
registry trial for the drug to provide additional data on the
Moveover, a phase III trial evaluating Leukotac for the treatment
of steroid-refractory acute graft versus host disease is ongoing
in the EU. Data from the trial is expected to be released in the
end of 2014 or early 2015.
Currently, we have a Neutral recommendation on Jazz Pharma. The
stock carries a Zacks Rank #3 (Hold rating) in the short run.
Pharma stocks, which currently look more attractive, are
). Both these companies carry a Zacks Rank #1 (Strong Buy).
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.